

Consultations in Molecular Diagnostics

Constitutional Duplication of a Region of Chromosome Yp Encoding *AMELY*, *PRKY*, and *TBL1Y*

Implications for Sex Chromosome Analysis and Bone Marrow Engraftment Analysis

Kathleen M. Murphy, Julie S. Cohen,
Amy Goodrich, Patricia P. Long, and
Constance A. Griffin

*From the Department of Pathology, Johns Hopkins Medical
Institutions, Baltimore, Maryland*

Amelogenin has chromosome X (*AMELX*) and Y (*AMELY*) homologs that can be differentiated based on the length of polymerase chain reaction (PCR) amplification products. In addition to being useful for gender identification, analysis of amelogenin has utility for monitoring bone marrow engraftment in patients after a sex-mismatched bone marrow transplant, characterizing sex chromosome abnormalities, and for forensic purposes for analyzing mixtures of male and female DNA. Here, we describe two brothers in which PCR analysis demonstrated twofold greater *AMELY* products compared with *AMELX* products. Karyotype and X/Y fluorescence *in situ* hybridization analysis demonstrated a single copy of the X and Y chromosomes without any identifiable abnormalities. Oligonucleotide comparative genomic hybridization array analysis demonstrated a duplication of a portion of chromosome Yp that encompassed a region of at least 2.6 Mb but not greater than 4.0 Mb. The amplified region contains the genes *AMELY*, transducin (β)-like 1 protein Y (*TBL1Y*), and protein kinase Y (*PRKY*). To our knowledge, duplication of this region has not previously been reported. The family history is unremarkable, and the brothers are without apparent dysmorphic features. Although this and other genetic variants involving *AMELY* are uncommon, one should use caution when using amelogenin for sex chromosome analysis and bone marrow engraftment analysis. (*J Mol Diagn* 2007, 9:408–413; DOI: 10.2353/jmoldx.2007.060198)

The Y chromosome is unique in that it is clonally inherited from father to son (with the exception of two small pseudoautosomal regions). The male-specific region of the Y chromosome appears to code for at least 27 distinct proteins or protein families, some of which have been implicated in gonadal sex reversal, Turner syndrome, graft rejection, and spermatogenic failure.¹ These syndromes often result from deletions within the Y chromosome or abnormal interchange between chromosomes X and Y.

Many Y-linked genes have X homologs that code for similar protein isoforms. The functional difference (if any) between the X and Y homologs of most of these genes is not well understood. One of the degenerate genes, amelogenin, has X and Y homologs located on Xp22.1-22.3 (*AMELX*) and Yp11.2 (*AMELY*). Polymerase chain reaction (PCR) amplification with single primer pairs can differentiate the *AMELX* and *AMELY* homologs due to the difference in length of the amplification products. This difference is commonly exploited for gender identification of clinical and forensic specimens. The most commonly used amelogenin PCR-based assay uses a primer pair that spans a 6-bp deletion within intron 1 of the X homolog.² Amplification of this region has been incorporated into several commercially available multiplex short tandem repeat (STR) reactions. These multiplex assays have utility for identity/forensic and paternity testing purposes. In addition to these qualitative applications, these assays can be used quantitatively by comparing the relative peak heights or peak areas of the amplification products. Some authors have proposed that comparing the *AMELX*- and *AMELY*-specific peak heights can have

Accepted for publication January 22, 2007.

Address reprint requests to Kathleen M. Murphy, Ph.D., Park Bldg., Room SB202, 600 North Wolfe St., Baltimore, MD 21287. E-mail: kmurphy4@jhmi.edu.

clinical utility for monitoring bone marrow engraftment in patients after a sex-mismatched bone marrow transplant,³ for characterizing sex chromosome abnormalities such as Klinefelter syndrome (XXY),² and for forensic purposes for quantification of the relative X and Y contribution in mixtures of male and female DNA.⁴ Here, we describe two brothers who have a constitutional duplication of a portion of the short arm of chromosome Y that was initially identified by amelogenin analysis.

Materials and Methods

DNA Isolation

DNA was isolated from all peripheral blood and bone marrow specimens using the Qiagen EZ1 automated nucleic acid extraction instrument and reagents or QIAamp DNA Mini kit spin columns according to the manufacturer's instructions (Qiagen, Valencia, CA).

Amelogenin Analysis

PCR amplification was performed using the AmpF/STR Profiler kit (Applied Biosystems, Foster City, CA) that detects nine microsatellite loci and the amelogenin locus. The amelogenin primer pair amplifies a region of intron 1 that spans a 6-bp deletion in *AMELX* compared with *AMELY*.² Thermal cycling and capillary electrophoresis were performed according to the manufacturer's instructions. In brief, the PCR conditions were 95°C for 11 minutes; followed by 28 cycles of 94°C for 1 minute, 59°C for 1 minute, and 72°C for 1 minute; followed by 60°C for 45 minutes. After amplification, 1 μ l of multiplex PCR product was mixed with 9 μ l of deionized formamide/GeneScan-500 [ROX] size standard solution (Applied Biosystems). Samples were denatured at 95°C for 2 minutes and placed on ice for at least 1 minute before analysis on the ABI 3100 capillary electrophoresis instrument (Applied Biosystems).

Amplification of a region spanning exon and intron 4 of amelogenin was performed using a previously described primer set that spans a 3-bp deletion in *AMELX* compared with *AMELY*.⁵ PCR amplification was performed in 25- μ l reactions containing 200 μ mol/L of each dNTP, 0.8 μ mol/L of each primer, and 1.25 U of *Taq* Gold polymerase (Applied Biosystems). Primers were 5'-FAM-CCCTT-GAAGTGGTACCAGAGCA-3' (AMEL-U1) and 5'-GCAT-GCCTAATATTTTCAGGAATA-3' (AMEL-D1). Reactions were thermal cycled as follows: one cycle of 95°C for 9 minutes; followed by 25 cycles of 95°C for 30 seconds, 57°C for 30 seconds, and 72°C for 30 seconds; followed by one cycle of 72°C for 7 minutes. Products were analyzed by capillary electrophoresis as described above.

Analysis of Protein Kinase X and Y Genes (*PRKX* and *PRKY*) and Zinc Finger X and Y Genes (*ZFX* and *ZFY*)

A PCR was designed to amplify exon 8 of the *PRKX* and *PRKY* genes. The primer set spans a 3-bp deletion in

PRKY, producing a *PRKY* product that is 3 bases shorter than the *PRKX* product. PCR amplification was performed in 25- μ l reactions containing 200 μ mol/L of each dNTP, 0.8 μ mol/L of each primer, and 1.25 U of *Taq* Gold polymerase (Applied Biosystems). Primers were 5'-FAM-TTTTGTTTCTTTCTGTCCATACTTAAAG-3' (PRK-F) and 5'-TCCCAAACCACTCAACTG-3' (PRK-R). Reactions were subjected to thermal cycling as follows: one cycle of 95°C for 9 minutes; followed by 25 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds; followed by one cycle of 72°C for 7 minutes. Products were analyzed by capillary electrophoresis as described above.

A PCR assay was designed to amplify exon 3 of the *ZFX* and *ZFY* genes. The primer set spans a 3-bp deletion in *ZFX*, producing a *ZFX* product that is 3 bases shorter than the *ZFY* product. PCR amplification was performed in 25- μ l reactions containing 200 μ mol/L of each dNTP, 0.8 μ mol/L of each primer, and 1.25 U of *Taq* Gold polymerase (Applied Biosystems). Primers were 5'-FAM-TGTGCATAACTTTGTTCCCTGATG-3' (ZF-F) and 5'-AG-CACTTGCTCAGGAATGATG-3' (ZF-R). Reactions were subjected to thermal cycling as follows: one cycle of 95°C for 9 minutes; followed by 28 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds; followed by one cycle of 72°C for 7 minutes. Products were analyzed by capillary electrophoresis as described above.

Karyotype and XY Fluorescence in Situ Hybridization (FISH)

The G-banded metaphase karyotype was obtained from B-cell stimulated and unstimulated cells from a bone marrow aspirate of the proband at time of diagnosis of his lymphoma and from phytohemagglutinin-stimulated lymphocytes 3 years after bone marrow transplant, using standard techniques. Centromere enumeration probe X α satellite and centromere enumeration probe Y satellite III DNA FISH probes (Vysis/Abbott Molecular, Des Plaines, IL) were used to evaluate interphase and metaphase cells from the phytohemagglutinin-stimulated lymphocytes following the manufacturer's protocol.

High-Density Array Comparative Genomic Hybridization

A custom 2 \times 105,000 high-density oligonucleotide array was designed using eArray v4.5 software (Agilent Technologies, Santa Clara, CA). Each array contained 4554 control oligonucleotide probes, 18,148 probes on chromosome Y, and 82,298 probes on chromosome X. Comparative genomic hybridization (CGH) was performed by Agilent Technologies according to standard protocol. In brief, genomic DNA (0.5 to 1.0 mg) and male reference DNA (Promega Corporation, Madison, WI) were digested with *AluI* and *RsaI* (Promega) at 37°C for 2 hours and then heat-inactivated at 65°C for 20 minutes. The reaction was then used directly as a template for a genomic DNA

labeling reaction using random primers and the exo-Klenow fragment in the Agilent Genomic Labeling Kit Plus (Agilent Technologies). Test and reference DNA samples were labeled with either Cy3- or Cy5-dUTP according to the manufacturer's protocol for 2 hours at 37°C. After heat inactivation at 65°C for 10 minutes, the labeled DNA products were purified using Microcon YM-30 filtration devices (Millipore, Inc., Bedford, MA) and brought to a volume of 80.5 μ l with nuclease-free water. The DNA yield and level of dye incorporation were then measured using the ND-1000 spectrophotometer. Appropriate Cy5 and Cy3-labeled DNA sample pairs were combined and mixed with human Cot-1 DNA (Invitrogen, Carlsbad, CA), Agilent 10X Blocking Agent, and Agilent 2X Hybridization Buffer. Samples were heated at 95°C for 3 minutes, incubated for 30 minutes at 37°C, and then hybridized to Agilent custom 2 \times 105,000 Human Genome CGH microarrays using Agilent SureHyb chambers. The hybridization chambers were then placed in a 65°C rotisserie oven and rotated at 20 rpm for 40 hours. The arrays were washed and dried according to the procedures described in Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis protocol version 4. Microarray slides were scanned immediately using an Agilent microarray scanner. Data were extracted using the Feature Extraction software v9.1.

Results and Discussion

The patient is a 39-year-old white male who was diagnosed with diffuse large B-cell non-Hodgkin's lymphoma with a bulky mediastinal mass approximately 6 years ago. He was treated with standard doses of chemotherapy and radiation therapy and then underwent an allogeneic bone marrow transplant with his brother as the donor. As part of routine workup before the patient's bone marrow transplant, peripheral blood specimens from the patient and his donor were evaluated using the AmpFISTR Profiler kit (Applied Biosystems), which detects nine STR loci and the amelogenin locus. This evaluation of polymorphic differences between the patient and donor allows for quantification of chimerism after transplantation. Analysis of the amelogenin locus of both the patient and his donor identified the *AMELX*- and *AMELY*-specific peaks; however, the *AMELY* peak was approximately twofold greater in height and area than the *AMELX* peak in both individuals (Figure 1). The average Y:X ratio from at least two replicates was 1.9:1 for the donor and 2.0:1 for the patient before transplant. Since the bone marrow transplantation, the patient has been evaluated for chimerism three times. The STR results of two informative loci were consistent with the patient having 100% donor engraftment. Consistent with the donor's amelogenin pattern before transplant, in each of the three follow-up analyses, the average amelogenin Y:X ratio (from at least two replicates each) was approximately 1.9:1. Review of 102 cases of males run in our laboratory showed an average amelogenin Y:X ratio of 0.96:1 with SD of 0.09. The highest Y:X ratio seen in this group of males was 1.2:1. Thus the Y:X ratio seen for both the patient and his brother (donor) was more than




Figure 1. Capillary electrophoresis analysis of amplification of intron 1 (top) and exon/intron 4 (bottom) of amelogenin. Horizontal axis is size in bases. Vertical axis is fluorescence intensity. Shown are results from the patient before bone marrow transplant (pre-BMT), donor, and a representative normal male. *AMELX*- and *AMELY*-specific peaks are identified by X and Y, respectively. The area of each peak is shown in parentheses.

9 SD greater than the average Y:X ratio observed in our laboratory. These results suggested that both brothers had an extra copy of the *AMELY* gene.

To confirm the apparent extra copy of *AMELY*, we used an additional amelogenin primer set approximately 700 bp downstream of the AmpFISTR Profiler primer set, which spans a 3-bp deletion in *AMELX* compared with *AMELY*. Amplification of 10 normal males demonstrated an average Y/X ratio of 0.98:1 with a SD of 0.046. Amplification of the patient and donor specimens demonstrated Y/X ratios of 2.1:1 and 2.2:1, respectively (Figure 1). These results support the conclusion that both brothers carry an additional copy of the *AMELY* gene.

It has been suggested that quantitative analysis of amelogenin can identify sex chromosome aneuploidy. For example, Sullivan et al² demonstrated that DNA from XYY individuals gave an *AMELY/AMELX* ratio of 1.8:1, whereas individuals with XXY genotype gave a 1:1.8 ratio. In this case, however, metaphase analysis of 30 cells from the bone marrow of the patient before his bone marrow transplant found a normal male karyotype of 46,XY in all cells analyzed. Karyotype and X/Y FISH analysis of a specimen after transplant from the patient demonstrated a single copy of the X and Y chromosomes without any identifiable abnormalities (Figure 2). Thus the extra copy of *AMELY* identified in these brothers was not due to an extra copy of the Y chromosome.

We then analyzed two additional genes on chromosome Yp that have X and Y homologs that can be distinguished by PCR product size. The *PRK* genes have X




Figure 2. Partial karyotype (A) and XY FISH (B) on metaphase and interphase cells demonstrated a single copy of chromosomes X and Y without identifiable abnormalities.




Figure 3. Capillary electrophoresis analysis of amplified products from genes *ZF* (top) and *PRK* (bottom). Horizontal axis is size in bases. Vertical axis is fluorescence intensity. Shown are results from the patient before transplant, the donor, and a representative normal male. The X and Y homologs of each gene are identified by X and Y, respectively. The area of each peak is shown in parentheses.

and Y homologs located on Xp22.3 (*PRKX*) and Yp11.2 (*PRKY*), respectively. The *PRKY* gene is located approximately 0.35 Mb centromeric to *AMELY*. To differentiate *PRKX* and *PRKY*, we designed a PCR to encompass a 3-bp deletion in *PRKY* compared with *PRKX*. Amplification of 10 normal males demonstrated an average *PRKY/PRKX* ratio of 0.87:1, with a SD of 0.026. Amplification of the patient and donor specimens demonstrated *PRKY/PRKX* ratios of approximately 1.7:1, which is almost exactly twofold greater than the average *PRKY/PRKX* ratio seen in our normal male population (Figure 3). These data were similar to the amelogenin results.

The *ZF* genes have X and Y homologs located at Xp22.1 (*ZFX*) and Yp11.2 (*ZFY*), respectively. *ZFY* is located approximately 3.9 Mb telomeric to *AMELY*. To differentiate *ZFX* and *ZFY*, we designed a PCR to amplify exon 3 of *ZF*, encompassing a 3-bp deletion in *ZFX* compared with *ZFY*. Amplification of 10 normal males demonstrated an average *ZFY/ZFX* ratio of 1.21:1, with a SD of 0.084. Amplification of the patient and donor specimens demonstrated *ZFY/ZFX* ratios that were very similar to that of the normal population (1.25:1 and 1.31:1, respectively, Figure 3). Taken together, the data suggested that both brothers carried a duplication of a portion of chromosome Yp that included *PRKY* and *AMELY*, but not *ZFY*.

To confirm the apparent duplication on chromosome Yp, we performed CGH using a custom-designed high-density oligonucleotide array. The patient's genomic

DNA (pre-transplant) and a male reference DNA were labeled with either Cy3 or Cy5 and then hybridized to a custom-designed array with 18,148 probes on chromosome Y and 82,298 probes on chromosome X. The experiment was performed twice, using the test and control DNA labeled in opposite colors (dye flip). Results of chromosome X analysis showed no copy number changes (data not shown). Analysis of chromosome Y demonstrated a duplication in chromosome Yp that encompassed a region of at least 2.6 Mb but not greater than 4.0 Mb (Figure 4). To our knowledge, duplication of this region has not previously been reported. We are unable to determine the exact breakpoints for this duplication with high confidence using CGH because this region is flanked by repetitive sequences, and therefore the number and density of CGH probes in the flanking regions is low. There are previous reports describing constitutional deletions in this region.^{6–11} The exact breakpoint for most of these deletions have not been determined, but many of these deletions appear to be greater than 1 Mb, and one was reported to be 2.5 Mb. These deletions significantly overlap the region we show to be duplicated. In addition, Repping et al¹² have recently reported inversion of a similar region of chromosome Yp in 16 of 47 Y chromosomes that represented branches of a worldwide genealogical tree. The 3.6-Mb inversion they identified is flanked by nonpalindromic inverted repeats (IR3), which flank the duplication identified here (Figure 4). Repping et al¹² suggested that the inversions that they identified originated via ectopic homologous recombination between the IR3 repeats. Thus, this region on chromosome arm Yp seems to be a hotspot for mutation/rearrangement, allowing for deletion, inversion, and now duplication of this region.

The CGH data demonstrate that the amplified region contains the three genes *AMELY*, *PRKY*, and Transducin (β)-like 1 protein Y (*TBL1Y*) and may contain all or part of the testis-specific protein Y (*TSPY*) gene family. The three genes known to be duplicated are single-copy genes located within the X-degenerate sequence of chromosome Y, and all have X-linked homologs, *AMELX*, *PRKX*, and *TBL1X*, respectively. *PRKX* and *PRKY* are members of the cAMP-dependent serine threonine protein kinase gene family and are ubiquitously expressed.^{13,14} Although *PRKX* has been implicated in renal epithelial cell migration and morphogenesis,¹⁵ and in granulocyte/




Figure 4. Oligonucleotide CGH analysis of the Y chromosome of the patient before transplant. The gray line to the right represents the patient/control fluorescence intensity ratios (patient labeled in Cy5, control in Cy3). The dark line to the left represents fluorescent intensities obtained from a second hybridization in which the dyes have been reversed (control/patient). An expanded view of the duplicated region is shown to the right, demonstrating the genes in this region.

macrophage lineage differentiation,^{16,17} the function of *PRKY* is essentially unknown. The *TBL1* gene family has at least three members: *TBL1X*, *TBL1Y*, and *TBL1R*, an autosomal homolog located on chromosome 3. Partial deletion of *TBL1X* appears to be related to X-linked recessive late-onset sensorineural deafness.¹⁸ *TBL1Y* differs from other members of the family in tissue expression pattern and function and cannot completely compensate for a lack of *TBLX*.¹⁹ Therefore *TBL1Y* may play other, yet unknown, unique roles in males.

AMELX and *AMELY* are highly conserved extracellular matrix proteins expressed during tooth enamel development.²⁰ *AMELX* is expressed at levels tenfold higher than *AMELY*, and mutations in *AMELX* result in the congenital enamel defect termed amelogenesis imperfecta.^{21,22} In contrast, deletions of *AMELY* have been reported in apparently healthy males.^{6–10} These deletions occur more frequently in certain ethnic populations and may reflect a common ancestor for at least some of these chromosomes.¹¹ Some of the deletions also appear to include deletion of *TBL1Y* and *PRKY*.^{6,10}

The *TSPY* gene family is based on a 20.4-kb repeat unit and contains approximately 35 copies of *TSPY* genes in a highly regular tandem arrangement.¹ *TSPY* expression is limited to the testis where it is believed to function as a proliferation factor during spermatogenesis, although its exact biological function remains to be elucidated. *TSPY* has been implicated as a putative oncogene involved in testicular tumorigenesis.^{23,24} Because of the repetitive nature of this region, the oligonucleotide probe density in this region is low, resulting in uncertainty as to whether all or part of the *TSPY* gene family is included in the duplicated region.

The duplication described here occurs in two brothers of Italian descent and is presumed to be inherited from their father. The family history is unremarkable, and the brothers are without apparent dysmorphic features. Specifically, there is no history of male-related infertility, cancer (other than the patient), or teeth abnormalities (given the involvement of the amelogenin gene). The lack of a phenotype associated with this duplication may explain why this genetic variant has not been previously identified. We have analyzed more than 700 males using the AmpF/STR Profiler reaction as part of bone marrow transplant monitoring and have not previously observed an unequal Y/X ratio in an apparently healthy male, suggesting that this duplication is a relatively rare event.

An additional copy of the entire Y chromosome (XYY syndrome) occurs in approximately 1 in 1000 newborn males. Although the clinical phenotype is variable, many XYY individuals are phenotypically normal and are never diagnosed.²⁵ Therefore, the lack of phenotype in these brothers with a duplication of a portion of chromosome Yp may not be surprising. Interestingly, it has been suggested that a constitutional XYY genotype may be associated with an increased risk for leukemia and lymphoma in such individuals, but this is tenuous (previously reviewed²⁶). The finding of a male with lymphoma and a duplication of only a portion of chromosome Yp may be of interest to this ongoing controversy.

In conclusion, we believe that this is the first report describing a constitutional duplication in the region of chromosome Yp that includes *AMELY*, *PRKY*, and *TBL1Y*. This region appears to be a hotspot for genetic events, which can result in deletion, inversion, or duplication of this region. From the literature and our observation, it appears that these events do not result in an appreciable phenotype. However, the resulting copy number changes can result in incorrect interpretation of amelogenin analysis. In this case, duplication of *AMELY* could have led to sex chromosome interpretation as XYY. Deletions in the region containing *AMELY* result in such individuals being falsely genotyped as female.^{6–8} Both duplication and deletion of *AMELY* can also result in erroneous bone marrow engraftment analysis results. We therefore recommend caution when using amelogenin analysis for sex chromosome analysis or bone marrow engraftment analysis. Sex chromosome abnormalities identified by amelogenin analysis should be confirmed by XY FISH and/or karyotyping. For bone marrow engraftment analysis, the amelogenin pattern before transplant of both the patient and donor should be analyzed closely. As recommended previously,²⁷ at least two loci should be used for all analyses after transplant.

Acknowledgments

We thank Mr. Will Ferguson for technical assistance with the CGH data and Drs. Denise Batista and Gail Stetton for valuable discussions and comments.

References

1. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, Brown LG, Repping S, Pyntikova T, Ali J, Bieri T, Chinwalla A, Delehaunty A, Delehaunty K, Du H, Fewell G, Fulton L, Fulton R, Graves T, Hou SF, Latrielle P, Leonard S, Mardis E, Maupin R, McPherson J, Miner T, Nash W, Nguyen C, Ozersky P, Pepin K, Rock S, Rohlfing T, Scott K, Schultz B, Strong C, Tin-Wollam A, Yang SP, Waterston RH, Wilson RK, Rozen S, Page DC: The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature* 2003, 423:825–837
2. Sullivan KM, Mannucci A, Kimpton CP, Gill P: A rapid and quantitative DNA sex test: fluorescence-based PCR analysis of X-Y homologous gene amelogenin. *Biotechniques* 1993, 15:636–638, 640–641
3. Toren A, Rechavi G, Nagler A: Minimal residual disease post-bone marrow transplantation for hemato-oncological diseases. *Stem Cells* 1996, 14:300–311
4. Mannucci A, Sullivan KM, Ivanov PL, Gill P: Forensic application of a rapid and quantitative DNA sex test by amplification of the X-Y homologous gene amelogenin. *Int J Legal Med* 1994, 106:190–193
5. Haas-Rochholz H, Weiler G: Additional primer sets for an amelogenin gene PCR-based DNA-sex test. *Int J Legal Med* 1997, 110:312–315
6. Santos FR, Pandya A, Tyler-Smith C: Reliability of DNA-based sex tests. *Nat Genet* 1998, 18:103
7. Thangaraj K, Reddy AG, Singh L: Is the amelogenin gene reliable for gender identification in forensic casework and prenatal diagnosis? *Int J Legal Med* 2002, 116:121–123
8. Steinlechner M, Berger B, Niederstatter H, Parson W: Rare failures in the amelogenin sex test. *Int J Legal Med* 2002, 116:117–120
9. Chang YM, Burgoyne LA, Both K: Higher failures of amelogenin sex test in an Indian population group. *J Forensic Sci* 2003, 48:1309–1313
10. Lattanzi W, Di Giacomo MC, Lenato GM, Chimienti G, Vogliano G, Resta N, Pepe G, Guanti G: A large interstitial deletion encompassing

- the amelogenin gene on the short arm of the Y chromosome. *Hum Genet* 2005, 116:395–401
11. Chang YM, Perumal R, Keat PY, Yong RY, Kuehn DL, Burgoyne L: A distinct Y-STR haplotype for Amelogenin negative males characterized by a large Y(p) 11.2 (DYS458-MSY1-AMEL-Y) deletion. *Forensic Sci Int* 2007, 166:115–120
 12. Repping S, van Daalen SK, Brown LG, Korver CM, Lange J, Marszałek JD, Pyntikova T, van der Veen F, Skaletsky H, Page DC, Rozen S: High mutation rates have driven extensive structural polymorphism among human Y chromosomes. *Nat Genet* 2006, 38:463–467
 13. Klink A, Schiebel K, Winkelmann M, Rao E, Horsthemke B, Ludecke HJ, Claussen U, Scherer G, Rappold G: The human protein kinase gene PKX1 on Xp22.3 displays Xp/Yp homology and is a site of chromosomal instability. *Hum Mol Genet* 1995, 4:869–878
 14. Schiebel K, Mertz A, Winkelmann M, Glaser B, Schempp W, Rappold G: FISH localization of the human Y-homolog of protein kinase PRKY (PRKY) to Yp11.2 and two pseudogenes to 15q26 and Xq12→q13. *Cytogenet Cell Genet* 1997, 76:49–52
 15. Li X, Li HP, Amsler K, Hyink D, Wilson PD, Burrow CR: PRKX, a phylogenetically and functionally distinct cAMP-dependent protein kinase, activates renal epithelial cell migration and morphogenesis. *Proc Natl Acad Sci USA* 2002, 99:9260–9265
 16. Semizarov D, Glesne D, Laouar A, Schiebel K, Huberman E: A lineage-specific protein kinase crucial for myeloid maturation. *Proc Natl Acad Sci USA* 1998, 95:15412–15417
 17. Glesne D, Huberman E: Smad6 is a protein kinase X phosphorylation substrate and is required for HL-60 cell differentiation. *Oncogene* 2006, 25:4086–4098
 18. Bassi MT, Ramesar RS, Caciotti B, Winship IM, De Grandi A, Riboni M, Townes PL, Beighton P, Ballabio A, Borsani G: X-linked late-onset sensorineural deafness caused by a deletion involving OA1 and a novel gene containing WD-40 repeats. *Am J Hum Genet* 1999, 64:1604–1616
 19. Yan HT, Shinka T, Kinoshita K, Sato Y, Umeno M, Chen G, Tsuji K, Unemi Y, Yang XJ, Iwamoto T, Nakahori Y: Molecular analysis of TBL1Y, a Y-linked homologue of TBL1X related with X-linked late-onset sensorineural deafness. *J Hum Genet* 2005, 50:175–181
 20. Nakahori Y, Takenaka O, Nakagome Y: A human X-Y homologous region encodes "amelogenin." *Genomics* 1991, 9:264–269
 21. Chen E, Piddington R, Decker S, Park J, Yuan ZA, Abrams WR, Rosenbloom J, Feldman G, Gibson CW: Regulation of amelogenin gene expression during tooth development. *Dev Dyn* 1994, 199:189–198
 22. Lagerström M, Dahl N, Nakahori Y, Nakagome Y, Backman B, Landegren U, Pettersson U: A deletion in the amelogenin gene (AMG) causes X-linked amelogenesis imperfecta (AIH1). *Genomics* 1991, 10:971–975
 23. Tsuchiya K, Reijo R, Page DC, Distechi CM: Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. *Am J Hum Genet* 1995, 57:1400–1407
 24. Lau Y, Chou P, Iezzoni J, Alonzo J, Komuves L: Expression of a candidate gene for the gonadoblastoma locus in gonadoblastoma and testicular seminoma. *Cytogenet Cell Genet* 2000, 91:160–164
 25. Abramsky L, Chapple J: 47,XXY (Klinefelter syndrome) and 47,YYY: estimated rates of and indication for postnatal diagnosis with implications for prenatal counselling. *Prenat Diagn* 1997, 17:363–368
 26. Limacher JM, Girard-Lemaire F, Jeandidier E, Chenard-Neu MP, Kassem M, Flori E, Bergerat JP: Gastrointestinal stromal tumor in an XYY/XY male. *Cancer Genet Cytogenet* 2002, 133:152–155
 27. Swierczynski SL, Hafez MJ, Philips J, Higman MA, Berg KD, Murphy KM: Bone marrow engraftment analysis after granulocyte transfusion. *J Mol Diagn* 2005, 7:422–426